Hyperkalemia is frequently seen in patients with chronic renal failure, chronic kidney disease, and in patients with acute or chronic kidney disease complicated by drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) system. The treatment of hyperkalemia varies depending on the severity and accompanying symptoms and comorbidities. In 2015, the US Food and Drug Administration approved patiromer a high capacity, oral potassium binder currently for the treatment of hyperkalemia. Other new treatments such as sodium zirconium cyclosilicate (ZS-9) are in development and may provide alternatives to practitioners caring for patients with hyperkalemia.
Ratings and Reviews
To review this course, please login.Login